APO Research
Talk to an analyst

APO RESEARCH · REPORT

Toxoid Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Toxoid Vaccines Market Outlook and Growth Opportunities 2026

22 December 2025195 pages

Choose your research edition.

Industry ResearchToxoid Vaccines Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Toxoid Vaccines Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Toxoid Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Toxoid Vaccines Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Toxoid Vaccines Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Toxoid Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Toxoid Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Toxoid Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Toxoid Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Toxoid Vaccines market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Toxoid Vaccines market include Shenzhen Kangtai Biological Products, Merck, Pfizer, GlaxoSmithKline, AstraZeneca, Sanofi Pasteur, Panacea Biotec, Emergent Biosolutions and Bharat Biotech, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Toxoid Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Toxoid Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Toxoid Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Toxoid Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Toxoid Vaccines Segment by Company

Shenzhen Kangtai Biological Products

Merck

Pfizer

GlaxoSmithKline

AstraZeneca

Sanofi Pasteur

Panacea Biotec

Emergent Biosolutions

Bharat Biotech

Bausch Health

Astellas Pharma

Toxoid Vaccines Segment by Type

Tetanus

Monovalent Tetanus Toxoid (TT)

Pertussis (DTaP)

Diphtheria and Tetanus (DT)

Diphtheria

Toxoid Vaccines Segment by Application

Government Organizations

Hospitals And Clinics

Research

Others

Toxoid Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Toxoid Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Toxoid Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Toxoid Vaccines significant trends, drivers, influence factors in global and regions.

6. To analyze Toxoid Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Toxoid Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Toxoid Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Toxoid Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Toxoid Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Toxoid Vaccines industry.

Chapter 3: Detailed analysis of Toxoid Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Toxoid Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Toxoid Vaccines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Toxoid Vaccines Industry Trends Table 2. Toxoid Vaccines Industry Drivers Table 3. Toxoid Vaccines Industry Opportunities and Challenges Table 4. Toxoid Vaccines Industry Restraints Table 5. Global Toxoid Vaccines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Toxoid Vaccines Revenue Share by Company (2021-2026) Table 7. Global Toxoid Vaccines Sales Volume by Company (k units) & (2021-2026) Table 8. Global Toxoid Vaccines Sales Volume Share by Company (2021-2026) Table 9. Global Toxoid Vaccines Average Price (US$/unit) of Company (2021-2026) Table 10. Global Toxoid Vaccines Company Ranking, (2024-2026) & (USD Million) Table 11. Global Toxoid Vaccines Key Company Manufacturing Base & Headquarters Table 12. Global Toxoid Vaccines Company, Product Type & Application Table 13. Global Toxoid Vaccines Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Toxoid Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Tetanus Table 18. Significant Companies of Monovalent Tetanus Toxoid (TT) Table 19. Significant Companies of Pertussis (DTaP) Table 20. Significant Companies of Diphtheria and Tetanus (DT) Table 21. Significant Companies of Diphtheria Table 22. Global Toxoid Vaccines Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 23. Global Toxoid Vaccines Sales Volume by Type (2021-2026) & (k units) Table 24. Global Toxoid Vaccines Sales Volume by Type (2027-2032) & (k units) Table 25. Global Toxoid Vaccines Sales Volume Share by Type (2021-2026) Table 26. Global Toxoid Vaccines Sales Volume Share by Type (2027-2032) Table 27. Global Toxoid Vaccines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Toxoid Vaccines Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Toxoid Vaccines Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Toxoid Vaccines Sales Value Share by Type (2021-2026) Table 31. Global Toxoid Vaccines Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Government Organizations Table 33. Significant Companies of Hospitals And Clinics Table 34. Significant Companies of Research Table 35. Significant Companies of Others Table 36. Global Toxoid Vaccines Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global Toxoid Vaccines Sales Volume by Application (2021-2026) & (k units) Table 38. Global Toxoid Vaccines Sales Volume by Application (2027-2032) & (k units) Table 39. Global Toxoid Vaccines Sales Volume Share by Application (2021-2026) Table 40. Global Toxoid Vaccines Sales Volume Share by Application (2027-2032) Table 41. Global Toxoid Vaccines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Toxoid Vaccines Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Toxoid Vaccines Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Toxoid Vaccines Sales Value Share by Application (2021-2026) Table 45. Global Toxoid Vaccines Sales Value Share by Application (2027-2032) Table 46. Global Toxoid Vaccines Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 47. Global Toxoid Vaccines Sales by Region (2021-2026) & (k units) Table 48. Global Toxoid Vaccines Sales Market Share by Region (2021-2026) Table 49. Global Toxoid Vaccines Sales by Region (2027-2032) & (k units) Table 50. Global Toxoid Vaccines Sales Market Share by Region (2027-2032) Table 51. Global Toxoid Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Toxoid Vaccines Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Toxoid Vaccines Sales Value Share by Region (2021-2026) Table 54. Global Toxoid Vaccines Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Toxoid Vaccines Sales Value Share by Region (2027-2032) Table 56. Global Toxoid Vaccines Market Average Price (US$/unit) by Region (2021-2026) Table 57. Global Toxoid Vaccines Market Average Price (US$/unit) by Region (2027-2032) Table 58. Global Toxoid Vaccines Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 59. Global Toxoid Vaccines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Toxoid Vaccines Sales by Country (2021-2026) & (k units) Table 61. Global Toxoid Vaccines Sales Market Share by Country (2021-2026) Table 62. Global Toxoid Vaccines Sales by Country (2027-2032) & (k units) Table 63. Global Toxoid Vaccines Sales Market Share by Country (2027-2032) Table 64. Global Toxoid Vaccines Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Toxoid Vaccines Sales Value Market Share by Country (2021-2026) Table 66. Global Toxoid Vaccines Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Toxoid Vaccines Sales Value Market Share by Country (2027-2032) Table 68. Shenzhen Kangtai Biological Products Company Information Table 69. Shenzhen Kangtai Biological Products Business Overview Table 70. Shenzhen Kangtai Biological Products Toxoid Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Shenzhen Kangtai Biological Products Toxoid Vaccines Product Portfolio Table 72. Shenzhen Kangtai Biological Products Recent Development Table 73. Merck Company Information Table 74. Merck Business Overview Table 75. Merck Toxoid Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Merck Toxoid Vaccines Product Portfolio Table 77. Merck Recent Development Table 78. Pfizer Company Information Table 79. Pfizer Business Overview Table 80. Pfizer Toxoid Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Pfizer Toxoid Vaccines Product Portfolio Table 82. Pfizer Recent Development Table 83. GlaxoSmithKline Company Information Table 84. GlaxoSmithKline Business Overview Table 85. GlaxoSmithKline Toxoid Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. GlaxoSmithKline Toxoid Vaccines Product Portfolio Table 87. GlaxoSmithKline Recent Development Table 88. AstraZeneca Company Information Table 89. AstraZeneca Business Overview Table 90. AstraZeneca Toxoid Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. AstraZeneca Toxoid Vaccines Product Portfolio Table 92. AstraZeneca Recent Development Table 93. Sanofi Pasteur Company Information Table 94. Sanofi Pasteur Business Overview Table 95. Sanofi Pasteur Toxoid Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Sanofi Pasteur Toxoid Vaccines Product Portfolio Table 97. Sanofi Pasteur Recent Development Table 98. Panacea Biotec Company Information Table 99. Panacea Biotec Business Overview Table 100. Panacea Biotec Toxoid Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Panacea Biotec Toxoid Vaccines Product Portfolio Table 102. Panacea Biotec Recent Development Table 103. Emergent Biosolutions Company Information Table 104. Emergent Biosolutions Business Overview Table 105. Emergent Biosolutions Toxoid Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Emergent Biosolutions Toxoid Vaccines Product Portfolio Table 107. Emergent Biosolutions Recent Development Table 108. Bharat Biotech Company Information Table 109. Bharat Biotech Business Overview Table 110. Bharat Biotech Toxoid Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. Bharat Biotech Toxoid Vaccines Product Portfolio Table 112. Bharat Biotech Recent Development Table 113. Bausch Health Company Information Table 114. Bausch Health Business Overview Table 115. Bausch Health Toxoid Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 116. Bausch Health Toxoid Vaccines Product Portfolio Table 117. Bausch Health Recent Development Table 118. Astellas Pharma Company Information Table 119. Astellas Pharma Business Overview Table 120. Astellas Pharma Toxoid Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 121. Astellas Pharma Toxoid Vaccines Product Portfolio Table 122. Astellas Pharma Recent Development Table 123. Key Raw Materials Table 124. Raw Materials Key Suppliers Table 125. Toxoid Vaccines Distributors List Table 126. Toxoid Vaccines Customers List Table 127. Research Programs/Design for This Report Table 128. Authors List of This Report Table 129. Secondary Sources Table 130. Primary Sources List of Figures Figure 1. Toxoid Vaccines Product Image Figure 2. Global Toxoid Vaccines Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Toxoid Vaccines Sales Value (2021-2032) & (US$ Million) Figure 4. Global Toxoid Vaccines Sales (2021-2032) & (k units) Figure 5. Global Toxoid Vaccines Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Toxoid Vaccines Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Tetanus Image Figure 10. Monovalent Tetanus Toxoid (TT) Image Figure 11. Pertussis (DTaP) Image Figure 12. Diphtheria and Tetanus (DT) Image Figure 13. Diphtheria Image Figure 14. Global Toxoid Vaccines Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Toxoid Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Toxoid Vaccines Sales Volume Share by Type (2021-2032) Figure 17. Global Toxoid Vaccines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Toxoid Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Toxoid Vaccines Sales Value Share by Type (2021-2032) Figure 20. Government Organizations Image Figure 21. Hospitals And Clinics Image Figure 22. Research Image Figure 23. Others Image Figure 24. Global Toxoid Vaccines Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global Toxoid Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Toxoid Vaccines Sales Volume Share by Application (2021-2032) Figure 27. Global Toxoid Vaccines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Toxoid Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Toxoid Vaccines Sales Value Share by Application (2021-2032) Figure 30. Global Toxoid Vaccines Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 31. Global Toxoid Vaccines Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Toxoid Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Toxoid Vaccines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Toxoid Vaccines Sales Value (2021-2032) & (US$ Million) Figure 35. North America Toxoid Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Toxoid Vaccines Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Toxoid Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Toxoid Vaccines Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Toxoid Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Toxoid Vaccines Sales Value (2021-2032) & (US$ Million) Figure 41. South America Toxoid Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Toxoid Vaccines Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Toxoid Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Toxoid Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Toxoid Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Toxoid Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Toxoid Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Toxoid Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Toxoid Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Toxoid Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Toxoid Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Toxoid Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Toxoid Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Toxoid Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Toxoid Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Toxoid Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Toxoid Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Toxoid Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Toxoid Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Toxoid Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Toxoid Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Toxoid Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Toxoid Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Toxoid Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Toxoid Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Toxoid Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Toxoid Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Toxoid Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Toxoid Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Toxoid Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Toxoid Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Toxoid Vaccines Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Toxoid Vaccines Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Tetanus
  • Monovalent Tetanus Toxoid (TT)
  • Pertussis (DTaP)
  • Diphtheria and Tetanus (DT)
  • Diphtheria
Applications
  • Government Organizations
  • Hospitals And Clinics
  • Research
  • Others
Companies covered
  • Shenzhen Kangtai Biological Products
  • Merck
  • Pfizer
  • GlaxoSmithKline
  • AstraZeneca
  • Sanofi Pasteur
  • Panacea Biotec
  • Emergent Biosolutions
  • Bharat Biotech
  • Bausch Health
  • Astellas Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Toxoid Vaccines Sales Value (2021-2032)
  4. 1.2.2 Global Toxoid Vaccines Sales Volume (2021-2032)
  5. 1.2.3 Global Toxoid Vaccines Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Toxoid Vaccines Market Dynamics
  1. 2.1 Toxoid Vaccines Industry Trends
  2. 2.2 Toxoid Vaccines Industry Drivers
  3. 2.3 Toxoid Vaccines Industry Opportunities and Challenges
  4. 2.4 Toxoid Vaccines Industry Restraints
3 Toxoid Vaccines Market by Company
  1. 3.1 Global Toxoid Vaccines Company Revenue Ranking in 2025
  2. 3.2 Global Toxoid Vaccines Revenue by Company (2021-2026)
  3. 3.3 Global Toxoid Vaccines Sales Volume by Company (2021-2026)
  4. 3.4 Global Toxoid Vaccines Average Price by Company (2021-2026)
  5. 3.5 Global Toxoid Vaccines Company Ranking (2024-2026)
  6. 3.6 Global Toxoid Vaccines Company Manufacturing Base and Headquarters
  7. 3.7 Global Toxoid Vaccines Company Product Type and Application
  8. 3.8 Global Toxoid Vaccines Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Toxoid Vaccines Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Toxoid Vaccines Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Toxoid Vaccines Market by Type
  1. 4.1 Toxoid Vaccines Type Introduction
  2. 4.1.1 Tetanus
  3. 4.1.2 Monovalent Tetanus Toxoid (TT)
  4. 4.1.3 Pertussis (DTaP)
  5. 4.1.4 Diphtheria and Tetanus (DT)
  6. 4.1.5 Diphtheria
  7. 4.2 Global Toxoid Vaccines Sales Volume by Type
  8. 4.2.1 Global Toxoid Vaccines Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Toxoid Vaccines Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Toxoid Vaccines Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Toxoid Vaccines Sales Value by Type
  12. 4.3.1 Global Toxoid Vaccines Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Toxoid Vaccines Sales Value by Type (2021-2032)
  14. 4.3.3 Global Toxoid Vaccines Sales Value Share by Type (2021-2032)
5 Toxoid Vaccines Market by Application
  1. 5.1 Toxoid Vaccines Application Introduction
  2. 5.1.1 Government Organizations
  3. 5.1.2 Hospitals And Clinics
  4. 5.1.3 Research
  5. 5.1.4 Others
  6. 5.2 Global Toxoid Vaccines Sales Volume by Application
  7. 5.2.1 Global Toxoid Vaccines Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Toxoid Vaccines Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Toxoid Vaccines Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Toxoid Vaccines Sales Value by Application
  11. 5.3.1 Global Toxoid Vaccines Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Toxoid Vaccines Sales Value by Application (2021-2032)
  13. 5.3.3 Global Toxoid Vaccines Sales Value Share by Application (2021-2032)
6 Toxoid Vaccines Regional Sales and Value Analysis
  1. 6.1 Global Toxoid Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Toxoid Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global Toxoid Vaccines Sales by Region: 2021-2026
  4. 6.2.2 Global Toxoid Vaccines Sales by Region (2027-2032)
  5. 6.3 Global Toxoid Vaccines Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Toxoid Vaccines Sales Value by Region (2021-2032)
  7. 6.4.1 Global Toxoid Vaccines Sales Value by Region: 2021-2026
  8. 6.4.2 Global Toxoid Vaccines Sales Value by Region (2027-2032)
  9. 6.5 Global Toxoid Vaccines Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Toxoid Vaccines Sales Value (2021-2032)
  12. 6.6.2 North America Toxoid Vaccines Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Toxoid Vaccines Sales Value (2021-2032)
  15. 6.7.2 Europe Toxoid Vaccines Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Toxoid Vaccines Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Toxoid Vaccines Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Toxoid Vaccines Sales Value (2021-2032)
  21. 6.9.2 South America Toxoid Vaccines Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Toxoid Vaccines Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Toxoid Vaccines Sales Value Share by Country, 2025 VS 2032
7 Toxoid Vaccines Country-level Sales and Value Analysis
  1. 7.1 Global Toxoid Vaccines Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Toxoid Vaccines Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Toxoid Vaccines Sales by Country (2021-2032)
  4. 7.3.1 Global Toxoid Vaccines Sales by Country (2021-2026)
  5. 7.3.2 Global Toxoid Vaccines Sales by Country (2027-2032)
  6. 7.4 Global Toxoid Vaccines Sales Value by Country (2021-2032)
  7. 7.4.1 Global Toxoid Vaccines Sales Value by Country (2021-2026)
  8. 7.4.2 Global Toxoid Vaccines Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Toxoid Vaccines Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Toxoid Vaccines Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Toxoid Vaccines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Toxoid Vaccines Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Toxoid Vaccines Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Toxoid Vaccines Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Toxoid Vaccines Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Toxoid Vaccines Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Toxoid Vaccines Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Toxoid Vaccines Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Toxoid Vaccines Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Toxoid Vaccines Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Toxoid Vaccines Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Toxoid Vaccines Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Toxoid Vaccines Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Toxoid Vaccines Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Toxoid Vaccines Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Toxoid Vaccines Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Toxoid Vaccines Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Toxoid Vaccines Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Toxoid Vaccines Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Toxoid Vaccines Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Toxoid Vaccines Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Toxoid Vaccines Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Toxoid Vaccines Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Toxoid Vaccines Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Toxoid Vaccines Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Toxoid Vaccines Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Toxoid Vaccines Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Toxoid Vaccines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Shenzhen Kangtai Biological Products
  2. 8.1.1 Shenzhen Kangtai Biological Products Company Information
  3. 8.1.2 Shenzhen Kangtai Biological Products Business Overview
  4. 8.1.3 Shenzhen Kangtai Biological Products Toxoid Vaccines Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Shenzhen Kangtai Biological Products Toxoid Vaccines Product Portfolio
  6. 8.1.5 Shenzhen Kangtai Biological Products Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Toxoid Vaccines Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Merck Toxoid Vaccines Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Toxoid Vaccines Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Toxoid Vaccines Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 GlaxoSmithKline
  20. 8.4.1 GlaxoSmithKline Company Information
  21. 8.4.2 GlaxoSmithKline Business Overview
  22. 8.4.3 GlaxoSmithKline Toxoid Vaccines Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline Toxoid Vaccines Product Portfolio
  24. 8.4.5 GlaxoSmithKline Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca Toxoid Vaccines Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Toxoid Vaccines Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 Sanofi Pasteur
  32. 8.6.1 Sanofi Pasteur Company Information
  33. 8.6.2 Sanofi Pasteur Business Overview
  34. 8.6.3 Sanofi Pasteur Toxoid Vaccines Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Sanofi Pasteur Toxoid Vaccines Product Portfolio
  36. 8.6.5 Sanofi Pasteur Recent Developments
  37. 8.7 Panacea Biotec
  38. 8.7.1 Panacea Biotec Company Information
  39. 8.7.2 Panacea Biotec Business Overview
  40. 8.7.3 Panacea Biotec Toxoid Vaccines Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Panacea Biotec Toxoid Vaccines Product Portfolio
  42. 8.7.5 Panacea Biotec Recent Developments
  43. 8.8 Emergent Biosolutions
  44. 8.8.1 Emergent Biosolutions Company Information
  45. 8.8.2 Emergent Biosolutions Business Overview
  46. 8.8.3 Emergent Biosolutions Toxoid Vaccines Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Emergent Biosolutions Toxoid Vaccines Product Portfolio
  48. 8.8.5 Emergent Biosolutions Recent Developments
  49. 8.9 Bharat Biotech
  50. 8.9.1 Bharat Biotech Company Information
  51. 8.9.2 Bharat Biotech Business Overview
  52. 8.9.3 Bharat Biotech Toxoid Vaccines Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Bharat Biotech Toxoid Vaccines Product Portfolio
  54. 8.9.5 Bharat Biotech Recent Developments
  55. 8.10 Bausch Health
  56. 8.10.1 Bausch Health Company Information
  57. 8.10.2 Bausch Health Business Overview
  58. 8.10.3 Bausch Health Toxoid Vaccines Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Bausch Health Toxoid Vaccines Product Portfolio
  60. 8.10.5 Bausch Health Recent Developments
  61. 8.11 Astellas Pharma
  62. 8.11.1 Astellas Pharma Company Information
  63. 8.11.2 Astellas Pharma Business Overview
  64. 8.11.3 Astellas Pharma Toxoid Vaccines Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Astellas Pharma Toxoid Vaccines Product Portfolio
  66. 8.11.5 Astellas Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Toxoid Vaccines Value Chain Analysis
  2. 9.1.1 Toxoid Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Toxoid Vaccines Sales Mode & Process
  6. 9.2 Toxoid Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Toxoid Vaccines Distributors
  9. 9.2.3 Toxoid Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst